Promoting Cardiac Repair Through Simple Engineering of Nanoparticles with Exclusive Targeting Capability Toward Myocardial Reperfusion Injury by Thermal Resistant Microfluidic Platform

Zehua Liu,Wenhua Lian,Qiang Long,Ruoyu Cheng,Giulia Torrieri,Baoding Zhang,Artturi Koivuniemi,Mohammad Mahmoudzadeh,Alex Bunker,Han Gao,Hongbin He,Yun Chen,Jouni Hirvonen,Rongbin Zhou,Qiang Zhao,Xiaofeng Ye,Xianming Deng,Helder A. Santos

DOI: https://doi.org/10.1002/adfm.202204666

IF: 19

2022-01-01

Advanced Functional Materials

Abstract:Nanoparticle (NP)‐based intravenous administration represents the most convenient cardiac targeting delivery routine, yet, there are still therapeutic issues due to the lack of targeting efficiency and specificity. Active targeting methods using functionalization of ligands onto the NPs’ surface may be limited by trivial modification procedures and reduced targeting yield in vivo. Here, a microfluidics assisted single step, green synthesis method is introduced for producing targeting ligands free heart homing NPs in a tailored manner. The generated β‐glucan‐based NPs exhibit precise and efficient targeting capability toward Dectin‐1 + monocytes/macrophages, which are confirmed as main pathogenesis mediators for cardiac ischemic/reperfusion (I/R) injury, with a sequentially enhanced cardiac NP accumulation, and this targeting strategy is exclusively suitable for cardiac I/R but not for other cardiovascular diseases, as confirmed both in murine and human model. Comparing to FDA‐approved nano‐micelles formulation, β‐glucan NPs loaded with NACHT, LRR, and PYD domains‐containing protein 3 (NLRP3) inflammasome inhibitor (CY‐09) exhibit better efficiency in ameliorating myocardial injury and heart failure induced by surgically induced I/R. These findings indicate a simple production of targeting‐ligand free NPs, and demonstrate their potential therapeutic applications for preclinical I/R‐induced cardiac injury amelioration.